Abstract: Breakpoint cluster region-Abelson (BCR-ABL1) translocation is the characteristic sign of chronic myeloid leukemia (CML). The quantitation of BCR-ABL1 messenger RNA is requisite for patients with CML, and reverse-transcription real-time quantitative polymerase chain reaction (RQ-PCR) is the method used most extensively in testing laboratories worldwide. Nevertheless, substantial variation in RQ-PCR results from different laboratories makes interlaboratory comparability inconvincible owing to the lack of standardization. To facilitate interlaboratory comparative assessment and international standardization, an international scale (IS) for BCR-ABL1 was proposed. The laboratory-specific conversion factors derived from the IS can convert local different values to the IS without changing procedures. The standardization of BCR-ABL1 also includes the whole analytical process, so it is noteworthy to pay attention to the quality control before BCR-ABL1 quantitative analysis. More importantly, the World Health Organization has validated a first genetic reference panel which is limited to the manufacturers to produce and calibrate secondary reference reagents. Also, a certified reference plasmid, ERM-AD623, was internationally accepted. This article mainly focuses on BCR-ABL1 measurement and these standardization efforts in progress.
Introduction
The breakpoint cluster region-Abelson (BCR-ABL1) is a fusion gene between the BCR gene and the ABL1 gene, producing the BCR-ABL1 fusion protein that constitutively activates tyrosine kinase. This fusion gene is generated by a chromosomal translocation, t(9;22)(q34;q11) ( Figure 1 ) [1] . This chromosome was discovered from peripheral blood (PB) samples in patients with chronic myeloid leukemia (CML) and named for the city where it was discovered, known as the Philadelphia (Ph) chromosome [2] . Until the 1980s, its pattern of formation became gradually clear. This chromosomal translocation leads to multiple subtypes that mainly depended on varying position of breakpoints. In ABL1 gene, upstream of exon a2 is the frequent location breakpoint. In BCR gene, there are three common break sites, breakpoints downstream of exon e13 or e14, e1 and e19, resulting in the e13a2 or e14a2, e1a2 and e19a2 fusion transcripts ( Figure 1 ) and encoding p210 oncoprotein, p190 oncoprotein and p230 oncoprotein, respectively. Besides, some other unusual breaks also occur and bring about relevant subtypes, such as e6a2, e8a2, e13a3 and e14a3 [3] .
The BCR-ABL1 fusion gene is detected in more than 95% of patients with CML, ~ 20%-25% of adult patients and 5% of children patients with acute lymphoblastic leukemia [4] . It is occasionally found in acute myeloid leukemia and acute mixed lineage leukemia. Therefore, in most cases, BCR-ABL1 measurement is applied for diagnosis and detection of patients with CML in clinical practice and classification of disease types. The tyrosine kinase activated by fusion gene changes the level of protein phosphorylation and inhibits cell apoptosis, responsible for occurrence of neoplastic disorders. Tyrosine kinase inhibitor (TKI) effectively inhibits the activity of the BCR-ABL1 protein in patients with CML by binding to the adenosine triphosphate-binding pocket of tyrosine kinase [5] . The International Randomized Study of Interferon and STI571 (IRIS) trial recommended imatinib as first-line therapy in CML and demonstrated the prognostic importance of detecting BCR-ABL1 burden to assess therapeutic effectiveness, monitor minimal residual disease (MRD) and detect relapse after treatment [6] . Responses to TKI therapy are judged from changes in BCR-ABL1 transcripts. They are associated with therapeutic outcomes and the evidence of properly adjusting the treatment strategy and individualizing patient management.
In almost all of the laboratories, reverse transcription real-time quantitative polymerase chain reaction (RQ-PCR) is used to quantify BCR-ABL1 transcripts from PB samples because of its high sensitivity and convenience compared with cytogenetic analysis and fluorescence in situ hybridization (FISH). Occasionally, bone marrow (BM) samples are also used for RQ-PCR [7] , and RQ-PCR is the only appropriate method to monitor molecular responses to treatment in different stages. However, its weakness is the process of standardization. The international scale (IS) and conversion factors (CFs) have epoch-making significance [8, 9] , setting a foundation for the development reference materials [10, 11] .
Methods to detect BCR-ABL1
The detection of BCR-ABL1 gene went through a series of development, from cytogenetics and immunology to molecular biology (Table 1) . Cytogenetics is important for clinical diagnosis in patients with CML which gives evidence of the presence of the Ph chromosome. However, its sensitivity is not enough to detect all chromosomal translocations successfully, and it has some limitations. In most cases, molecular testing is applied to detect early relapse after BM transplantation and monitor MRD because it has high sensitivity and specificity. Additionally, immunological methods are used to detect the oncoprotein which is encoded by the fusion gene in PB samples based on antigen-antibody binding reaction. The labeled antibodies bind to fusion proteins and the signals are detected by colorimetry or flow cytometry to identify the presence of fusion proteins [17] .
Cytogenetic analysis
Conventional cytogenetic method analyzes the structure and number of chromosomes to discover chromosome anomalies. Karyotype analysis can clearly visualize chromosomes at the stage of metaphase by banding techniques that subdivide each chromosome into a series of alternating bright and dull bands [12] . To detect the Ph chromosome, the BM samples from patients need to be cultured shortly to obtain chromosomes in metaphase. After special staining procedures (e.g. Giemsa, quinacrine mustard), the patterns of chromosomes are visible with a light microscope or fluorescence microscope. Karyotype analysis reveals a shorted chromosome 22 actually caused by a balance translocation between chromosome 9 and 22 [1] . Because conventional chromosome banding technique is limited to chromosomes in metaphase and hardly finds submicroscopic changes, FISH was developed in the late 1980s.
FISH can visualize cells in metaphase or interphase and specimens can be from BM, PB and other tissues. It is considered to be the province of molecular cytogenetics as it also involves nucleic acid probes based on cytogenetics [13] . FISH hybridizes nucleic acid probes (DNA probes or RNA probes) with chromosome-specific DNA sequences by denaturing genomic DNA. These probes are fluorochrome-labeled and the signals are observed with a fluorescence microscope [14] . The BCR-ABL1 fusion signal on the Ph chromosome is detected by FISH method using colored BCR and ABL DNA probes. Normally, there is red BCR signal (R) and green ABL signal (G) on the normal chromosomes 9 and 22, respectively. When BCR-ABL1 fusion gene is present, a fused red and green signal (F) is seen. In CML, the typical signal pattern of t(9;22) is 2F1R1G, these atypical signal patterns such as 1F1R2G, 1F2R1G and 1F1R1G associated with submicroscopic deletions of the derivative chromosome 9 [15] .
Compared with conventional cytogenetics, FISH needs less time to get results (usually within 48 hours) and has higher sensitivity to detect residual disease. Although results from conventional cytogenetics and FISH correlate well, cytogenetics would not be replaced by FISH completely for it can reveal additional abnormalities which may provide indications to prognosis [16] . FISH is useful to diagnose and assess effectiveness of treatment for neoplastic diseases in combination with conventional cytogenetic analysis.
Molecular testing
The PCR technique is not only for evaluating molecular responses to therapy and relapse, but also for diagnosis. Thus, PCR is used widely to measure BCR-ABL1 messenger RNA (mRNA) for its high sensitivity and specificity since it was initiated.
In the early days, qualitative PCR was extendedly used. It detects BCR-ABL1 gene through specific amplification of complementary DNA (cDNA) transcripts from RNA. Total RNA is extracted from blood or BM and then reverse transcribed into cDNA using an oligo primer; ultimately, target DNA sequence is generated using specific primers through PCR reaction involving a process of DNA denaturing, annealing and primer extension [22] . In nested PCR, two pairs of primers are used. The first pair of primers amplifies BCR-ABL1 gene and the second (nested primers) binds to the previous amplified sequence of interest to get a shorter product [18] . If the first PCR reaction has nonspecific products, they cannot be amplified in the second reaction. So the specificity of BCR-ABL1 diagnostic assays could be enhanced by nested primers. PCR products are observed by agarose gel electrophoresis to identify whether BCR-ABL1 transcripts are detectable.
In order to meet further clinical needs, PCR quantitation is necessary. Quantitative PCR for BCR-ABL1 transcripts can evaluate the level of disease burden for further individual therapy. Reverse transcription is also the first step in quantitative PCR. Besides primers, fluorophorelabeled oligonucleotide probe is needed in RQ-PCR process, so fluorescence emission is used to quantify the copies of BCR-ABL1. This oligonucleotide probe (Taqman system), which has a reporter fluorescent at the 5′ end and a quencher fluorescent at the 3′ end, hybridizes on the template. During the extension phase of the PCR reaction, the reporter and quencher are separated by Taq polymerase so the fluorescence can be detected by monitoring system [19] . PCR products in every cycle can be measured based upon the changes of fluorescence signals and final quantification is depended on a cycle threshold (Ct) value and standard curve because the Ct value is proportional to the starting amount of template. The Ct is the PCR cycle number when fluorescence signal reaches a threshold value of 10 times the standard deviation of baseline fluorescence emission [20] . The standard curve is generated based on the linear relationship between the amount of known template and Ct value.
Prospective methods
RQ-PCR quantification for BCR-ABL1 measurement is substantially affected by the process of experimental operation, efficiency of amplification, and standardization of reporting results in various laboratories [23] . As the development of BCR-ABL1 TKI promotes deeper molecular response, conventional RQ-PCR cannot completely predict treatment cessation or relapse [24] . To pursue further sensitivity and accuracy, as well as proper standard implement in BCR-ABL1 quantification, digital PCR (dPCR) is gradually popular in many medical laboratories. dPCR is the improvement of RQ-PCR. It achieves absolute quantification of the amplification of interest without a standard curve. In dPCR reaction, the sample is randomly distributed into hundreds or thousands of subreactions using microfluidic technology and each has PCR amplification separately. So some subreactions containing target templates have positive amplification and some do not have. Fluorescence signal in positive subreaction is caught and total quantitative analysis of results is based on Poisson distribution [21] . Also, dPCR is an ideal method to discover rare mutation [25] . Further, there are some more BCR-ABL1 detection methods. Extreme PCR shortens traditional PCR cycle time [26] . And the quantum chemistry method is proved to detect very low concentrations of DNA template (2.56 pm) [27] .
Harmonization in BCR-ABL1 measurement Harmonization in methodology and reporting results
The methodology used for identifying BCR-ABL1 transcripts has made great progress and RQ-PCR is the extensively used technique. Nevertheless, the standardization of results is the main problem to be solved. The whole process of BCR-ABL1 quantification, including RNA extraction from samples, RNA quality, reverse transcription, efficiency of PCR amplification, choice of control gene and expression of results, has obvious effects on final results [23] . To facilitate the development of standardization, a standardized protocol for Taqman-based RQ-PCR analysis was established in the Europe Against Cancer (EAC) program [19] . Experiments were performed in 26 laboratories from 10 countries, and the program validated EAC primers and probes, standardized RT and RQ-PCR protocol, compared different standard curves (RNA, cDNA and DNA plasmids), recommended statistical analysis and reference values at diagnosis for fusion gene transcripts detection in leukemia [19] . This program achieved a milestone for molecular monitoring. In 2005, a significant meeting took place at National Institutes of Health (NIH) in Bethesda also put forward the optimization of RQ-PCR methodology [8] . It recommended that blood samples are suitable for regular analysis, RT and RQ-PCR protocol formulated by the EAC can produce reliable results [28] , the performance characteristics of RQ-PCR assay should be measured to assure the results.
To normalize RNA quality and efficiency of reverse transcription, the EAC program evaluated the expression and suitability of three commonly control genes (ABL, B2M and GUSB) on the standardized protocol and finally proposed that ABL can be used as the most suitable internal control in RQ-PCR [29] . However, both wildtype and fused ABL genes were amplified in EAC study because of the design of primers for ABL, causing a lower ratio of BCR-ABL1/ABL% and underestimation of tumor cells. Another experiment recommended GUSB as the appropriate control gene for its similar expression level in normal samples and degradation kinetics to BCR-ABL1 transcripts [30] .
Even so, quite a few distinctions are still in the procedures in which RQ-PCR is carried out and results are reported in all laboratories. Since the absence of reference materials or calibrators, to obtain straight results, the IRIS study raised the log 10 reduction which could demonstrate the level of BCR-ABL1 burden after therapy [30] . The BCR-ABL1 values were expressed as a percentage of BCR levels (control gene) and the log reduction is relative to a baseline level obtained from the median value of BCR-ABL1 transcripts in blood samples from 30 untreated CML patients [31] . In addition, this study proposed that the log reduction from baseline was a good method to evaluate molecular responses in patients who achieved complete cytogenetic remission. Therefore, a reduction at least 3 log from baseline level is defined as a major molecular response (MMR), a predictor that means patients are more likely to have progression-free survival [31] . Different laboratories can adjust local values to this standardized scale to assess therapeutic efficiency.
Performance of the IS
The conference at NIH also discussed the expression of reported data and implied the log reduction was a relative value. It suggested that the standardized baseline mentioned above represent 100% on an IS and define MMR level (3 log reduction) as 0.10%. Meanwhile, the concept of CF was proposed that is derived from the value equivalent to MMR. CFs covert various values to the IS: BCR-ABL1 (local value) × CF = BCR-ABL1 (IS) [8] . The significance of CFs is that different laboratories standardize their results with no need to alter their procedures. The Adelaide Laoboratory (Australia) initiated the process of calculation and validation of CFs. These CFs are yielded from samples exchange between participating laboratories and reference laboratories. Each sample from the participating laboratory was again tested by the reference laboratory.
If there is a systematic bias, results generated by participating laboratory can be aligned to the IS by applying a CF. The calculation of laboratory-specific CFs is conducted as the antilog of the mean bias between log 10 -transformed values in each laboratory and log 10 -transformed values in the reference laboratory [9] . Subsequent validation is indispensable after the determination of CFs and this needs greater data analysis in two laboratories. Because certain alternations of assay designs in local laboratories may give rise to variation of CFs. The agreement between methods after conversion was evaluated, showing that an average difference achieved within ± 1.2-fold from reference method and 95% limits of agreement within ± 5-fold leading to a MMR concordance of 91% [9] .
The application of CFs promotes the spread of IS, but this conversion is circumscribed. The whole process of calculation and validation is complex, time-consuming and expensive on account of a large amount of data analysis. The changes of CFs resulted from changes in experimental procedures burden the whole process, from the above, limited laboratories can establish CFs [32] . Hence, it is imperative to pursue the development of reference materials or calibrators.
Achievements on BCR-ABL1 standardization
The goal of standardization for measurement relies on the reference measurement system, which is the basis of traceability of results [33] and comprised of reference measurement procedures, reference materials and reference measurement laboratories. There are many reference laboratories around the world; reference measurement procedures measure the reference materials and assign values. Here, reference materials are mainly discussed.
The first establishment of the World Health Organization (WHO) international reference panel for quantification of BCR-ABL1 mRNA is in 2010. This panel is composed by a set of four levels containing lyophilized K562 cells diluted in HL60 cells from 10% to 0.01% on the IS [10] . For there is no unanimous agreement on control gene, three common control genes (BCR, ABL and GUSB) are chosen. Ten laboratories had validated CFs participated in the value assignment of this panel according to different control genes. These values are standardized to IS by the application of CFs derived from sample exchange process. This WHO primary panel is a landmark in BCR-ABL1 standardization. Because production of the cell line mixture is limited, the panel is restricted to companies or laboratories that want to produce secondary reference reagents available to routine testing laboratories.
Thereafter, Asuragen, in collaboration with the international community, developed the secondary calibrator panels with synthetic Armored RNA Quant (ARQ) technology. Armored RNA is a kind of protein particle containing internal RNA sequence of interest and its coat protein effectively protects internal RNA from enzyme degradation [34] . Since this structure simulates the features of viral nucleic acid well, armored RNA is a good alternative for virus calibrators [34, 35] . The validation and calibration to IS of the ARQ calibrator panels are based on the WHO primary materials, and this international research involving the assessment of linearity, sensitivity, and imprecision demonstrated that the panels enable analytical calibration of local RQ-PCR assay within the context of IS standardization and improve the accuracy and precision of BCR-ABL1 measurement [36] . The panels also have been evaluated in a multicenter external quality assessment study and confirmed that they can facilitate global diffusion of BCR-ABL1 IS standardization in laboratories not yet standardized [37] . The ARQ IS calibrator panels are commercially available and make it easy and convenient to implement IS standardization. Also, ipsogen BCR-ABL1 Mbcr IS-MMR calibrator can be purchased from Qiagen bases on EAC program and can be calibrated on the WHO reference panel. It can report BCR-ABL1 IS results and have high sensitivity and accuracy for monitoring MRD [38] .
For some secondary calibrators made of RNA as referred previously exclude RNA extraction in the process of IS calibration, the first cell-based secondary reference panel anchored to the WHO primary panel was generated, with an additional MR 4.5 level ( ≥ 4.5 log reduction from IRIS baseline) [39] . The assignment of %BCR-ABL1 IS values is depended on reverse-transcript droplet digital PCR with ABL1, BCR and GUSB as reference genes. The MR 4.5 level can be used to evaluate the sensitivity and capability of the assays. Sample input for IS calibration was optimized in this study because of different linear dynamic ranges in different assays, then laboratories adopted the optimal sample input to assess the performance characteristics of BCR-ABL1 test on this secondary panel [39] . Results indicated that this cell-based reference panel can provide easier access to IS calibration.
It is worth mentioning that an automated cartridgebased detection system (GeneXpert; Cepheid) widely adopted for monitoring BCR-ABL1 transcripts also helps standardization. The GeneXpert system utilizes microfluidics to automate all steps involving RNA extraction, nested BCR and fluorescence detection. Therefore, the Xpert BCR-ABL Monitor assay greatly reduces hands-on experimental time, minimizes potential contamination and is a reliable method to detect BCR-ABL1 translocation [40, 41] . Subsequently, the system reports results of lotspecific with the WHO BCR-ABL1 standard and provides an IS CF to ensure calibration. And the results have good MMR concordance with reference laboratory [42] .
The availability of secondary calibrators makes calibration to the IS convenient and contributes to worldwide standardization. Thus, laboratories can make their reported results on the IS through samples exchange to derive CFs and commercial reference calibrator panels. An experiment designed to compare the two alignment strategies proved that the application of genetic reference materials to calibrate BCR-ABL1 quantification is compatible with the process of samples exchange [43] . Although no considerable data to show which is better, in principle, the use of calibrated reagents is generally accepted by vast majority of laboratories.
Another breakthrough in the development of reference materials is the advent of an internationally accepted certified reference material (CRM), EAM-AD623, a plasmid including BCR-ABL1 and three commonly used control genes (ABL1, BCR and GUSB) [11] . The e14a2 BCR-ABL1, BCR and GUSB transcripts were amplified and cloned into pUC18 to yield a new plasmid pIRMM0099. This study used dPCR to give absolute numbers of transcripts and there are six different copy number concentration levels. The set of six plasmid CRMs helps to calibrate the BCR-ABL1 measurements particularly monitor deep molecular responses and improve the accuracy of testing results before conversion to the IS. When BCR-ABL1 is undetectable, the copy numbers of control genes transcripts can estimate the test sensitivity [11] . The standardization on BCR-ABL1 measurement has made marked achievements, and reference materials provide convenience for IS calibration.
Clinical application of BCR-ABL1 measurement
The BCR-ABL1 fusion gene is both the hallmark and therapeutic target in CML and the measurement is mainly applied to monitor responses to treatment in patients to evaluate therapeutic efficacy and the transcripts level gives an indication of possible prognosis. At the beginning, complete hematological response is expected at 3 months for the criteria normalization of PB counts and no extramedullary involvement [44] . Cytogenetic response is based on cytogenetic analysis in BM samples, the absence of Ph + chromosomes (at least 20 cells in metaphase) meaning achievement of complete cytogenetic response (CCyR) that is closely related to promising remission [44, 45] .
The IRIS study demonstrated that imatinib can cause faster and substantial responses compared with interferon plus cytarabine, and analysis of the long-term data monitoring proved the evidence of the predictive value of molecular responses [31, 46] . It indicated that patients who achieved a CCyR or MMR had a significantly lower progression rates. Cytogenetic and molecular responses at 6, 12 and 18 months are the three landmarks to indicate that patients have continuous event-free survival (EFS), accelerated phase/blast crisis (AP/BC) and overall survival, or they do not [6, 47] . At 6 months, patients who obtained a BCR-ABL1 (IS) < 10% had an EFS rate > 85% at 84 months, much higher than those who did not. The achievement of an MMR at 12 and 18 months was associated with longterm outcome. Patients with an MMR at 12 months had a 91% EFS rate, compared with 79% in patients without an MMR. No patients progressed to AP/BC after achieving the MMR by 18 months and they had 95% EFS rate. Patients who had loss of CCyR, MMR, or increasing levels of BCR-ABL1 had increased rate of progression to AP/BC. Based on the importance of monitoring responses, BM cytogenetics is necessary at 3, 6 and 12 months until a CCyR has been achieved, and RQ-PCR for BCR-ABL1 transcript levels should be performed every 3 months until an MMR or CCyR has been achieved, then every 3-6 months, in line with the recommendations from the National Comprehensive Cancer Network and European Leukemia Net [48, 49] .
MMR is a milestone to monitor prognostic significance in patients undergoing treatment. However, deep molecular responses, the BCR-ABL1 transcripts level blow the MMR, were achieved in part of patients with the advent of new TKI therapy [50] . The term MR 4 ( ≥ 4 log reduction from IRIS baseline) is defined as either BCR-ABL1 level of ≤ 0.01% BCR-ABL1 (IS) or undetectable disease in cDNA with ≥ 10 000 ABL1 transcripts; MR 4.5 as ≤ 0.0032% BCR-ABL1 (IS) or undetectable disease in cDNA with ≥ 32 000 ABL1 transcripts, corresponding to the definition of the MMR [49, 51] . Deep molecular responses depend on the sensitivity and ability of testing laboratories, and achievements of deep responses correlate with better long-term prognosis and can be also regarded as indication for discontinuation of treatment in CML [52] .
Moreover, BCR-ABL kinase domain (KD) mutations are found in patients who are resistant to imatinib and they may have rising BCR-ABL1 levels [53] . The incidence of KD mutations has something to do with treatment failure and high risk of disease progression, so a study showed that KD mutations detection should be performed if there is a two-fold increase in BCR-ABL1 levels [54, 55] .
Summary
At present, the BCR-ABL1 measurement is widely applied to diagnose leukemia and monitor the efficacy of treatment for patients. Technology for detecting the fusion gene used frequently includes cytogenetic analysis, FISH and RQ-PCR. dPCR is becoming popular due to the absolute quantification of copy numbers for target gene. RQ-PCR assay is a superior tool to give a deeper assessment to treatment for CML patients after achieving a CCyR, however, the standardization of RQ-PCR is the main problem to be solved. Optimal clinical procedures for BCR-ABL1 measurement are tested and discussed, propelling the harmonization in methodology [19] . The proposal of the IS and CFs is a paramount milestone for standardizing BCR-ABL1 measurement. It facilitates interlaboratory comparison and the process of standardization. The establishment of CFs by exchange of reference standards gets internationally consistent agreement, yet it is not the most appropriate program to realize international standardization. Now, many laboratories and organizations are working on the development of reference materials and have made great achievements. Next efforts are the generation and evaluation of the secondary reference materials. As an ideal formulation of reference materials, the whole process of RQ-PCR should be involved and stability over a period time is essential. Plasmid calibrators cannot cover RNA extraction from patient specimens, and like cell lines or armed RNA, they are unlikely to completely behave as actual clinical samples, concerning sample collection, transport, storage, and other potential situations. Commutability and matrix effects of the reference materials should be also considered. To date, these existing reference materials only target the e13a2 or e14a2 fragments, other atypical subtypes relevant to minor patients with CML and other hematological disorders remain additional attention. Thus, standardization of BCR-ABL1 testing is still a challenging progress. Furthermore, deep molecular responses caused by new TKIs could result in more stable remission and need more comprehensive definitions and exploration.
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